1st Detect's Aviation Security Technology Ready to Support the U.S. Aviation Security Modernization Initiative
Globenewswire· 2025-12-12 21:25
1st Detect Corporation's detection and analysis mass spectrometry systems deployed worldwide offer the ability to reduce false alarms and strengthen checkpoint screeningAUSTIN, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced its support of the Department of Homeland Security’s (“DHS”) recent initiative to modernize aviation security screening and technology nationwide. On November 22, 2025, DHS Secretary Kristi Noem announced a $1 ...
Credicorp Ltd.: Announces 2026 Schedule for Quarterly Results and Conference Calls
Globenewswire· 2025-12-12 21:20
Lima, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Lima, Peru, December 12, 2025 – Credicorp Ltd. (“Credicorp”) (NYSE: BAP | BVL: BAP) announces to its shareholders and the market the schedule for issuing the 2026 quarterly earnings releases and hosting the corresponding conference calls: 1Q26Earnings Release – Thursday, May 14, 2026Conference Call – Friday, May 15, 2026 2Q26Earnings Release – Thursday, August 13, 2026Conference Call – Friday, August 14, 2026 3Q26Earnings Release – Monday, November 9, 2026Conference C ...
Vital Energy Stockholders Approve Merger with Crescent Energy
Globenewswire· 2025-12-12 21:20
TULSA, Okla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Vital Energy, Inc. (NYSE: VTLE) ("Vital Energy" or the "Company") today announced that, at a special meeting of Vital Energy stockholders held today, the stockholders of the Company approved the previously announced merger (the "Merger") between Vital Energy and Crescent Energy Company ("Crescent"). Vital Energy will file the final vote results for its special meeting on a Form 8-K with the U.S. Securities and Exchange Commission (the "SEC"). The Merger is ant ...
Edesa Biotech Reports Fiscal Year 2025 Results
Globenewswire· 2025-12-12 21:20
TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business. During the year, the company initiated manufacturing activities for a Phase 2 study of Edesa’s dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in patients with moderat ...
FireFly files Final Short Form Prospectus for Canadian Bought Deal Offering
Globenewswire· 2025-12-12 21:11
Final Short Form Prospectus Accessible on SEDAR+Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- FireFly Metals Ltd (ASX: FFM, TSX: FFM) (FireFly or Company) is pleased to announce that, in connection with its previously announced bought deal offering, it has filed a final short form prospectus dated 12 December 2025 (Final Prospectus) to qualify the distribution of 19,230,770 ordinary shares of the Company (Offered Shares) at ...
Parks! America, Inc. Reports Fourth Quarter and Full Year Fiscal Year 2025 Financial Results
Globenewswire· 2025-12-12 21:10
Management to host conference call on Monday, December 15, 2025, at 4:30 PM ET PINE MOUNTAIN, Georgia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Parks! America, Inc. (OTCQX: PRKA), today announced its financial results for the fourth fiscal quarter and fiscal year ended September 28, 2025. The summary information in this press release should not be used as the sole basis for making investment decisions. We encourage shareholders to read our complete Form 10-K, which has been posted on the Investor Info section of t ...
Ingredion Incorporated Declares Quarterly Dividend of $0.82 Per Share
Globenewswire· 2025-12-12 21:06
WESTCHESTER, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, announced today that its board of directors has declared a quarterly dividend of $0.82 per share on the Company’s common stock. The quarterly dividend will be payable on Jan. 20, 2026, to stockholders of record at the close of business on Jan. 2, 2026. For additional information about Ingredion Incorporated, including investor relations, financial updates, and upcoming ...
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globenewswire· 2025-12-12 21:05
CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December 11, 2025 (the “Grant Date”), the Company’s Board of Directors granted non-qualified stock options to purchase an a ...
ParaZero DefendAir Impresses German Bundesländer Police Leadership in Live Demonstration Organized by The Israeli Ministry of Defense
Globenewswire· 2025-12-12 21:05
Kfar Saba, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced the successful demonstration of its advanced DefendAir counter-UAS (C-UAS) system at a high-profile event organized by the International Defense Cooperation Directorate (SIBAT) at the Israel Ministry of Defense’s (IMOD) demonstration fa ...
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
Globenewswire· 2025-12-12 21:05
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today provides an update on the regulatory review in the EU for blarcamesine to treat early Alzheimer's disease. As ...